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Resumo 
A epilepsia é uma das mais prevalentes desordens neurológicas em todo o mundo, afetando 0.4-
1% da população mundial. De acordo com dados da Organização Mundial de Saúde a epilepsia 
é responsável por 1% dos encargos com doenças. O termo epilepsia inclui várias desordens 
neurológicas genéticas e adquiridas que têm em comum a ocorrência periódica e imprevisível 
de convulsões, isto é, de episódios de atividade neuronal excessiva. Embora estejam disponíveis 
vários fármacos antiepilépticos, estes não são eficazes em 30% dos pacientes que continuam a 
sofrer progressão da doença. Torna-se então imperativo encontrar novas terapias que previnam 
o início e/ou progressão desta desordem. 
Tradicionalmente a epilepsia tem sido considerada unicamente como uma doença neuronal. No 
entanto, na última década, vários estudos realizados em modelos animais de epilepsia e em 
tecido cerebral humano de pacientes com esta desordem demonstraram a influência e a 
contribuição de processos inflamatórios nos mecanismos de geração e recorrência dos ataques 
epiléticos. A neuroinflamação pode ser vista como uma resposta imune que têm como objetivo 
enfrentar uma ameaça que esteja a ocorrer no cérebro. No entanto, a inflamação pode ser tanto 
prejudicial como benéfica na resolução da lesão. Vários estudos demonstraram que um processo 
inflamatório ocorre em todos os tipos de epilepsia, mesmo nos tipos sem características da 
fisiopatologia inflamatória, tal como epilepsia do lobo temporal (TLE). TLE é um dos 
principais e mais perigosos tipos de epilepsia que afeta a zona do hipocampo. Estudos recentes 
mostraram que o estado de inflamação crónica nesta doença está de facto associado à morte 
neuronal, à ativação de células da glia e à expressão de fatores inflamatórios. As células da glia, 
nomeadamente astrócitos e microglia, têm um papel relevante na inflamação através da 
sobrexpressão e libertação de mediadores inflamatórios, tais como as citocinas. Estas proteínas 
possuem efeitos tanto na disfunção sináptica como na excitoxicidade e na morte neuronal que 
podem contribuir para a alteração da excitabilidade neuronal, levando à epileptogénese. As 
principais citocinas pro-inflamatórias envolvidas na geração e propagação das convulsões são 
o factor de necrose tumoral (TNF-α), a interleucina-1β (IL-1β) e a interleucina-6 (IL-6).  
Este estudo pretende avaliar a evolução dos eventos inflamatórios num modelo in vitro de 
epileptogénese. O estudo foca-se na morte celular, no estado de activação e morfologia dos 
astrócitos e da microglia, assim como na expressão das principais citocinas pro-inflamatórias 
envolvidas na epilepsia.  
Para realizar estes objetivos foram usadas culturas organotípicas de hipocampo, uma vez que, 
recentemente foi descrita a ocorrência de atividade epilética espontânea nestas culturas. Estas 
culturas são extremamente atrativas uma vez que as células se desenvolvem de forma 
semelhante às células in vivo, e podem ser mantidas por longos períodos de tempo permitindo 
uma manipulação e avaliação a longo prazo. O processo de corte do hipocampo para obtenção 
das fatias organotípicas representa um trauma bastante severo com o consequente 
desenvolvimento de conectividade anormal, que também se encontra descrito em tecido 
humano de pacientes com epilepsia. Por estes motivos, as culturas organotípicas de hipocampo 
são consideradas um modelo simples e útil no estudo da epileptogénese. As culturas foram 
preparadas a partir de ratos Sprague-Dawley com 6-7 dias de vida (P6-7). Todos os ensaios 
foram realizados em amostras obtidas a 7, 14 e 21 dias in vitro (DIV), de modo a estudar a 
morte celular e os marcadores de inflamação ao longo do tempo.  
A morte celular foi avaliada através da captação de iodeto de propídio (PI) e dos produtos de 
clivagem da α-II Espectrina (SBDP). O PI é um marcador fluorescente com a capacidade de se 
ligar aos ácidos nucléicos. Deste modo, ao entrar nas células cujas membranas estão danificadas 
(ou seja, em processo de morte celular) permite observá-las num microscópio de fluorescência. 
Os SBDP dão indicação sobre o tipo de morte celular que está a ocorrer nas células, uma vez 
que α-II Espectrina pode ser clivada por protéases envolvidas na morte celular, nomeadamente 
a calpaína (ativada tanto na necrose como na apoptose) e a caspase-3 (principal caspase ativada 
na apoptose), dando origem a produtos distintos. A ativação dos astrócitos e da microglia foi 
analisada por western blot através da expressão de marcadores específicos. Para os astrócitos 
utilizou-se como marcador a proteína acídica fibrilar glial (GFAP) e para a microglia a molécula 
de ligação ao cálcio ionizado 1 (Iba1). O ensaio de imunofluorescência, realizado com os 
marcadores referidos, foi efetuado para avaliar as alterações morfológicas destas células da glia, 
uma vez que a sua forma é indicadora do seu estado de ativação. Adicionalmente, a expressão 
de mRNA das citocinas, assim como dos seus receptores, foi quantificada por PCR quantitativo.  
O ensaio de morte celular por PI mostrou que a região CA1 do hipocampo é a zona mais 
sensível, o que está de acordo com a literatura. A zona CA1 sofre uma reorganização de 
conexões neuronais e apresenta uma maior concentração de recetores de glutamato, cuja 
activação pode conduzir à morte das células. Relativamente à progressão da morte celular, tanto 
os resultados do PI como os SBDP demonstraram um pico de morte celular a 14 DIV. Este 
resultado coincide com o início de atividade epiléptica espontânea observada neste modelo e 
considera-se ser uma consequência destes eventos. Neste trabalho apenas o SBDP resultante da 
clivagem da α-II Espectrina pela calpaína foi obtido. Não se obtive o SBDP resultante da 
clivagem da α-II Espectrina pela caspase-3, nem a forma ativa desta mesma caspase. Concluiu-
se assim que a morte celular neste modelo ocorre por necrose ou pela via de apoptose não 
dependente das caspases, uma vez que a calpaína atua em ambos os tipos de morte celular.  
A expressão do GFAP teve um ligeiro aumento ao longo do tempo, mas sem significado 
estatístico. No entanto, nas imagens de imunofluorescência pode observar-se a formação 
progressiva de uma cicatriz glial. Esta cicatriz é caracterizada pela presença de astrócitos com 
processos longos e entrelaçados a cobrir os neurónios, e tem como função restringir 
espacialmente a inflamação e o tecido danificado. De facto, a ocorrência de cicatriz glial 
generalizada, isto é, observável em todas as zonas do hipocampo, coincidiu com o pico de morte 
celular reportado neste estudo. O western blot indicou uma redução de cerca de 40% na 
expressão do marcador da microglia (Iba-1), tanto a 14 DIV como a 21 DIV, comparativamente 
a 7 DIV. O ensaio de imunofluorescência mostrou a ocorrência da morfologia “amoeboid”, 
característica de microglia activada e com maior expressão de Iba1 apenas a 7 DIV, tendo 
posteriormente ocorrido uma reversão para a morfologia ramificada, típica de microglia não 
ativa. 
A avaliação da expressão dos transcritos das citocinas indicou um aumento progressivo ao 
longo do tempo, relativamente à IL-1β e TNF-α. A IL-6 aumentou significativamente apenas a 
21 DIV. A expressão da maioria dos respectivos recetores das citocinas estudadas também 
mostrou um aumento significativo a 21 DIV. Apenas o recetor TNFR2 do TNF-α teve um 
aumento estatístico significativo, o que poderá indicar um aumento de sinalização anti-
apóptotica a 21 DIV, explicando a diminuição de morte celular obtida nesse tempo.  
Neste modelo de epileptogénese, obteve-se uma progressão de eventos inflamatórios com 
aumento de gliose e de citocinas inflamatórias, coincidente com o desenvolvimento da atividade 
epilética espontânea. Observou-se a ocorrência de astrogliose progressiva, enquanto a microglia 
reverteu para um estado inativado ao longo do tempo. Neste trabalho, a ativação da microglia 
parece estar relacionada com a lesão infligida pelo método de preparação das fatias de 
hipocampo, uma vez que a microglia atua muito rapidamente em situações de lesão (e também 
de infeção e/ou inflamação), sendo um dos seus principais papéis eliminar os restos celulares 
resultantes da morte das células. A ativação da microglia é também responsável por promover 
a ativação dos astrócitos, que representam neste modelo a fonte principal de produção dos 
mediadores inflamatórios, sendo assim responsáveis por perpetuar o estado de inflamação na 
epileptogénese. 
Este trabalho mostrou que o modelo de epileptogénese usado é bastante útil para explorar as 
funções das células da glia e da inflamação na epileptogénese e na progressão da epilepsia. 
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Abstract 
 
Epilepsy is one of the most common neurological disorders. The influence of inflammatory 
processes on epilepsy has increased in the last decade and recent studies show the contribution 
of astrocytes and microglia for the mechanisms of seizure onset and recurrence, through the 
overproduction and release of pro-inflammatory cytokines.  
The aim of this study was to explore the progression of inflammatory markers within the 
organotypic hippocampal slice model of epileptogenesis.  
An evaluation of cell death was performed through Propidium Iodide uptake assay and alphaII-
Spectrin cleavage. Astrogliosis and microglia activation were also assessed by western blot and 
by immunofluorescence assays, which used specific markers for astrocytes and microglia, glial 
fibrillary acidic protein (GFAP) and ionized calcium-binding molecule 1 (Iba1), respectively. 
Additionally, the transcript expression of the principal pro-inflammatory cytokines, involved in 
seizure generation and propagation (IL-1β, TNF-α and IL-6) and their receptors, was achieved 
through qPCR. All assays were carried out in slices with 7, 14 and 21 days in vitro (DIV).  
The majority of cell death was obtained in 14 DIV slices, which coincided with the onset of 
seizure-like activity in this model. Concerning glia activation, an upregulation of GFAP, with 
glial scar formation, was observed throughout culture time, while microglia changed from an 
activated amoeboid form to a resting ramified state. Transcript analysis of all pro-inflammatory 
cytokines revealed an increased expression over time in culture. However, statistical 
significance was solely achieved in 21 DIV slices. IL-1R1, TNFR2, and IL-6R expression were 
also upregulated in 21 DIV slices, while TNFR1 levels remained unchanged through time in 
culture.  
The results indicate an activity dependent inflammatory process, since at 21 DIV, when slices 
depict mixed interictal and ictal-like events, an upregulation of inflammatory mediators was 
observed in the organotypic model of epileptogenesis. More specifically, gliosis and increased 
expression of inflammatory mediators was achieved. 
Key words:  
Epilepsy, Neuroinflammation, Gliosis, Cytokines, Hippocampus  
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1 BACKGROUND 
1.1 Nervous System  
The nervous system consists of two main parts: the central nervous system (CNS) that contains 
the brain and spinal cord and the peripheral nervous system (PNS) that includes the somatic 
and autonomic system 1. The cellular unit of the nervous system is the neuron. However, the 
brain tissue is also composed by other very important cells, the glia. The neuron is an 
electrically excitable cell that processes and transmits information by electrical and chemical 
signals. Neurons are able to communicate with each other through the generation and 
propagation of nervous impulses and through the release of signalling molecules (the 
neurotransmitters), which are used to amplify and modulate signals between two neurons and 
also between neurons and other cells 2.  
1.2  Epilepsy 
Epilepsy is the third most common chronic brain disorder  affecting 0,4-1% of the world’s 
population 3,4. The International League Against Epilepsy defines epilepsy as an enduring 
propensity of recurrent epileptic seizures 5. These are characterized as symptomatic, 
hypersynchronous and paroxysmal depolarisations and high-frequency firing of populations of 
neurons in the CNS 6. Epileptogenesis are the mechanisms by which a normal brain becomes 
epileptic. These mechanisms lead to an imbalance between excitation and inhibition, which 
results in hyperexcitable neuronal population 6. However, the underlying mechanisms of 
epileptogenesis are not fully understood. Epileptogenesis includes several hallmarks, such as 
neuronal death, gliosis, inflammation and re-wiring, among others 7.  
Although there are an increasing number of treatment options, there is still no cure for epilepsy. 
Anti-epileptic drugs (AEDs) are the principal treatment and its basic mechanism is to restore 
the balance between inhibitory and excitatory transmission, leading to the suppression of 
seizure generation 8. Thus, it is relevant to highlight that most of the actual treatments are 
directed to neurons. However, the current antiepileptic drugs have two major drawbacks. First, 
recent studies have shown that only 70% of the patients can be successfully treated. Therefore, 
30% of the cases have refractory epilepsy 9. Secondly, the AEDs have risks of cognitive 
complications 10. Furthermore, the current available AEDs are mainly symptomatic, since they 
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only block seizures. AEDs do not affect the underlying pathology or progression of this disorder 
and it is therefore imperious to discover new therapies in order to prevent its onset and/or 
progression 11.  
Traditionally, epilepsy has been considered only a neuronal disease. However, a new direction 
was taken to fully understand the mechanisms of this neurological disorder 12. In the last decade, 
researchers have been dedicated to the excitatory and inflammatory effects of glia cells in this 
pathology. The direct neuromodulatory actions of inflammatory mediators, such as cytokines 
have been particularly explored 13. 
1.3  Temporal Lobe Epilepsy 
The hippocampus, compared to other structures, is an exquisitely seizure-prone structure 14, 
since the principal cells, within this structure, display propensities for epileptiform activity and 
seizures. However, it is not yet clear, whether the epilepsy is caused by hippocampal 
abnormalities or whether the damaged in hippocampus is due to cumulative effects of seizures 
15. In terms of anatomy, the hippocampus belongs to the limbic system and is located under the 
temporal lobes of the cerebral cortex.  
Temporal Lobe Epilepsy (TLE) is one of the most dangerous and frequent types of intractable 
epilepsy 16,17 and it has the most common structural abnormality in human epilepsy, defined as 
hippocampal sclerosis (HS) 17,18. HS consists of hippocampal atrophy involving an extensive 
and selective neuronal loss and gliosis, mostly in cornus ammonis (CA) 1 and dentate gyrus 
(DG) regions 19. Reactive gliosis is characterized by hypertrophy of glial cells 10. Another 
alteration in HS includes an aberrant mossy fiber sprouting, in which the mossy fiber axons of 
DG cells form synapses with themselves and with other granule cells (synaptic reorganization) 
20–22, thus creating a monosynaptic excitatory feedback 16,23,24. Actually, this feature has been 
noted in both animal models of epilepsy 25 and in human brain tissue from TLE patients 26.   
Although TLE is an epileptic disorder that does not feature a typical inflammatory 
pathophysiology, there are several evidences supporting the occurrence of an inflammatory 
state sustained by microglia, astrocytes and neurons and also by the presence of pro-
inflammatory mediators 27.  
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1.4  Neuroinflammation 
Inflammation is defined as a homeostatic phenomenon, consisting in the quick production of 
pro-inflammatory or anti-inflammatory mediators by both innate and adaptive immunity cell 
types 28. 
The CNS has historically been considered an immune-privileged site 29, since immune 
responses were thought to be constrained by the blood-brain-barrier (BBB) 27,30. This 
anatomical structure assures the separation between the nervous tissue and the peripheral 
environment 31, protecting the brain and maintaining its homeostasis 32. Nowadays, the 
existence of immune and inflammatory reactions in the CNS and their role in the development 
and progression of multiple neurodegenerative disorders has become clear 33. Moreover, the 
CNS is constituted by its own innate immune cells, the microglia cells, which constitute a major 
player of innate immune mechanisms 34,35.  
In most cases, neuroinflammation constitutes a beneficial process, being defined as a defense 
mechanism aimed to protect the CNS against insults such as infection, injury or trauma 36. This 
process is a result of resident parenchymal cells activation, such as microglia, astrocytes, and 
neurons, as well as via infiltration of immune cells from the periphery 37. The beneficial effects 
include the clearance of cellular debris and secretion of neurotrophic factors and cytokines 37. 
Whenever inflammatory process and immunosuppressive (e.g, tissue regeneration) pathways 
gets out of balance, a chronic neuroinflammation may arise. In this situation, inflammation 
becomes detrimental for brain tissue and results in cell dysfunction or death, contributing to the 
pathogenesis of several neurological conditions36,38,39.  
Over the last decade, as a result of supportive evidence in experimental models and in the 
clinical studies, the role of inflammation in the pathophysiology of seizures and epilepsy has 
received an increasing attention40. One major hallmark of neuroinflammation is the activation 
of glial cells, named reactive gliosis 41, which is also a characteristic frequently encountered in 
TLE patients and in epilepsy animal models 13,42,43. Both clinical and experimental evidences 
suggest a direct and reciprocal relationship between glia-mediated inflammatory processes and 
neuronal excitability and epileptogenesis 27,44-45. Thus, inflammation can be the consequence of 
recurrent seizures, as well as the cause of the underlying pathology 39. Experimental studies 
demonstrated that several insults can induce a cascade of chronic inflammatory processes in the 
CNS, which contribute to the development of epilepsy 46,47. This event is often associated with 
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neuronal cell death. In turn, the recurrence of spontaneous seizures can maintain the 
inflammation 48.  Inflammation can be induced by seizures and can persist for days, even after 
the termination of seizures 49-51. However, the mechanisms that lead to seizure-evoked 
inflammation are still unknown 52. Although cell loss does not induce inflammation in this 
context, dying cells may contribute to the perpetuation of the inflammatory process47,53. 
Noteworthy, most of neurodegenerative diseases are also characterized by the production of 
inflammatory mediators, such as cytokines 54-56.  
1.5  Glial cells  
Glia cells are involved in diverse neuronal functions, being the main role the support to the 
neurons during brain development and function 57. In CNS, glial cells can be divided into four 
major categories: microglia, astrocytes, radial glial cells, and oligodendrocytes 58. This study 
will focus in microglia and astrocytes, since these are the glial cells activated in pathological 
conditions.  
Nowadays, astrocytes have been considered to be functionally associated with the pre- and 
postsynaptic nerve terminals, as the third element of a structure known as “tripartite synapse” 
59,60. In the healthy brain, astroglia play a pivotal role in synapse regulation through metabolic 
processes, established in cooperation with neurons, such as energy supply and also synthesis 
and removal of neurotransmitters61-65. The production of inflammatory mediators (e.g., 
cytokines) by astrocytes is also involved in the regulation of synaptic activity 64. Several other 
functions have been attributed to astrocytes, such as ion  homeostasis and tissue repair 66,67. 
Microglia are the innate immune cell of the CNS, located within the brain parenchyma, in 
structures like hippocampus 64,68. These glial cells provide a defense in CNS against several 
pathological insults and have multiple morphological and functional profiles influenced by their 
surrounding environment 69-71. Normally, microglia cells are in a surveying (resting) state, 
monitoring their environment with a ramified morphology, resembling the dendritic cells from 
the innate immune system 72. In this state, microglia are able to sense neuronal and astrocytic 
activity and other physiological changes such as pH shifts, ion currents and neurotransmitter 
release37-73. Whenever activated, in response to injuries or to immunological stimuli, microglia 
change rapidly to a prime state (characterized by shortened processes and a rounder cell body) 
and subsequently to an amoeboid activated state 74. This morphology enables microglia to 
migrate, through the parenchyma toward the lesion sites, and to release inflammatory 
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mediators, such as cytokines 75. Only in the active state, microglia display endocytic and 
phagocytic activity and serve as antigen-presenting cells 30,37. Phagocytic activity plays a 
beneficial effect, as the regulation of homeostasis, through the clearance of cellular debris 
and/or toxic substances 76.  Moreover, due to their proliferation ability, microglial cells can also 
increase in number in response to a stimuli 77. These immune cells have a dual activity, since 
they can either promote neuronal survival and regeneration or contribute to neurodegeneration.  
Astrocytes, together with microglia, are responsible for the inflammatory and immune 
responses in the brain. Being astrocytes the major glial cell type of the CNS, researchers point 
to a great role played by these cells in neuroinflammatory processes 29. It has been demonstrated 
that astrocytic cells initiate and amplify inflammatory-mediated mechanisms involved in 
several human CNS diseases, including epilepsy 78,79. Studies, both in vitro and in vivo, 
argument that astrocytes are a major source and target of epileptogenic inflammatory signaling 
80. Likewise, in response to an insult or stress, astrocytes become reactive (activated), leading 
to the release of inflammatory mediators and growth factors that help regulate and resolve the 
inflammatory tissue response 63,75. However, in these situations, astrocytes do not respond as 
fast as microglia 81. Astrocytes proliferate and extend their processes around the injury site, 
which ultimately results in a scar formation 67,82,83.  
Since glia cells are implicated in the modulation of synaptic transmission, it is plausible to point 
that alterations in these cells may have a functional role in the hyperexcitability 84. In fact, 
alterations in the neurotransmitters cycle and induction of inflammatory molecules in epilepsy 
have been associated with glial cells’ activation (cytokines’ effects in epilepsy in section 1.6) 
27,85,86 . Consistent with this, manipulations of glial inflammatory processes are being 
considered as potential therapeutic targets for epilepsy.  
1.6  Cytokines 
Cytokines are considered as one of the primary classes of inflammatory regulators of innate and 
adaptive immune responses throughout the body, including the CNS 87. Being signaling 
molecules, cytokines act through specific receptors and signal transduction pathways to exert a 
particular biological response in the target cell 69. Although all cell types in the brain are capable 
to express cytokines and their respective receptors, its basal level of expression is quite low 27. 
However, followed CNS insults, cytokines are quickly overexpressed 27. Cytokines’ actions can 
be neuroprotective or neurotoxic in neurological diseases. For example, the transcriptional 
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pathway induced by cytokines can modulate cell death and survival and also synaptic 
reorganization and plasticity 88.  
In epilepsy, the overproduction of cytokines appears to be implicated in synaptic dysfunction, 
as well as in excitotoxicity and apoptotic neuronal death47,89,90. Excitotoxicity is a process of 
neuronal death triggered by excessive or prolonged activation of excitatory neurotransmitter 
receptors 91. This suggests that the release of cytokines by glia cells during seizures may 
contribute to seizure-mediated neuronal damage52. Regarding synaptic dysfunction, these 
inflammatory mediators have effects in the seizure threshold and in epileptic activity, which 
are important evidences that neuroinflammation has a vital role in the development of 
epilepsy52. The cytokine effects’ on neuronal survival and excitability seems to be mediated by 
interactions between these proteins and neurotransmitters 52.  
Several studies point to interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α) and 
interleukin-6 (IL-6) as the principal pro-inflammatory cytokines involved in seizure generation 
and propagation 49,92-94. Concerning other cytokines, there is still limited information about their 
role in seizure phenomena 34,95.  
1.7 IL-1β 
The pro-inflammatory cytokine IL-1 is a pivotal regulator of immune responses to pathogens 
and to injury and, not surprisingly, it has similar effects within the CNS 96. All the IL-1 family 
members are present within the brain 97, being IL-1β the most studied IL-1 in 
neuroinflammation and epilepsy 98,99.  
IL-1β is synthesized as a 31 kDa inactive precursor (pro-IL-1β) 100. Therefore, to become the 
bioactive 17 kDa form, the pro-IL-1β requires an enzymatic cleavage, by caspase-1, also known 
as IL-1β converting enzyme (ICE). The biological function of both IL-1β is mediated through 
the binding to interleukin-1 receptor type I (IL-1RI), which induces an association with the 
receptor-accessory protein (IL-1RAcP). This complex is able to initiate an intracellular signal 
through an adaptor protein, myeloid differentiation factor 88 (MyD88) 100,101. This is followed 
by an activation of several transcription factors, such as nuclear factor-κB (NF-κB), mitogen-
activated protein kinases (MAPKs), among others 101. IL-1β is considered a pivotal mediator, 
not only because of its ability to upregulate other inflammatory cytokines, such as IL-6 and 
TNF-α, but also because it is the first cytokine released in pathologic conditions 100,102.   
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A strong activation of IL-1β/IL-1R1 complex was already described in both glial and neuronal 
cells in the analysis of human brain specimens of TLE patients with hippocampal sclerosis 
103,104. Furthermore, and regarding IL-1β effects in synaptic transmission, an enhancement of 
neuronal excitability and also a decrease in seizure threshold were described in hippocampus 
and other seizure sensitive regions 105,106. Therefore, IL-1β is classified as pro-convulsive 
molecule, while inhibitors of its pathway may be powerful anticonvulsants 107.  
1.8  TNF-α 
TNF-α is a pleiotropic cytokine, playing pivotal roles in immunity, cell proliferation, 
differentiation and cell death through the activation of several downstream signaling cascades 
108.  
TNF is synthesized as a 26 kDa transmembrane protein precursor (mTNF) and cleaved into a 
17-kD mature soluble form (sTNF) by the metalloprotease TNF-α converting enzyme (TACE) 
109. The biological effects of TNF-α are mediated through the interaction with transmembrane 
receptors, namely TNF receptor type 1 (TNFR1 or p55) and type II (TNFR2 or p75) 108.  
Whereas TNFR1 is expressed in the majority of CNS cell types and activated by both mTNF 
and sTNF, TNFR2 is mainly expressed in microglia cells and only activated by mTNF 110.  
There are two main groups within the TNFR superfamily of receptors. The first group induces 
cell death signaling and is only carried out through TNFR1 (p55), since TNFR2 (p75) lacks a 
functional death domain (DD). Thereby, TNFR2 only signals for anti-apoptotic reactions, 
leading to the production of neurotrophic, neuroprotective and anticonvulsant factors 34. The 
TNF-α/TNFR1 complex is able to recruit several members of the caspase family of cell death 
proteases, such as the initiator caspase-8 and -10, which cleave effector caspases, particularly 
caspase-3 111,112. The second group can be constituted by both receptor types whenever they 
present the TRAF interacting motifs (TIM) domain, which binds to TNFR-associated factors 
(TRAFF) 113. The signal is carried out through this complex by the activation of transcription 
factors, such as NF-κB, Jun N-terminal kinases (JNK), and MAPKs 108. Recent studies have 
shown that, like IL-1β, TNF-α possesses neuromodulatory properties and is, thereby, able to 
increase neuronal excitability through several effects in neurotransmission mediated by TNFR1 
114,115. The consequence of TNF-α on seizures and on the determination of inflammatory 
processes towards neurodegeneration or neuroprotection, seems to depend on its level in the 
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brain and which receptor type is predominantly activated 69. In fact, TNFR1 is described as a 
pro-ictogenic factor, while TNFR2 plays an anti-ictogenic role 114.  
1.9  IL-6 
IL-6 is also recognized as a pleiotropic cytokine that was originally classified as a pro-
inflammatory cytokine. However several discoveries indicated that this interleukin has also 
anti-inflammatory properties 116. IL-6 has emerged as a key player in the nervous system, which 
is evident from its involvement not only in neuroinflammation, but also in several nervous 
system pathologies 116.  
This cytokine exerts its biological functions by binding to the non-signaling IL-6 receptor (IL-
6R). Therefore, the recruitment of additional receptor proteins is necessary to induce the 
signaling pathways 117. The IL-6/IL-6R complex specifically triggers the homodimerization of 
glycoprotein 130 (gp130) with the alpha subunit of IL-6R.  This, in turn, activates IL-6 signal 
transduction through intracellular tyrosine-kinases such as Janus kinases (JAK-1 and JAK-2) 
110,117,118.  
Similarly to IL-1β and TNF-α, IL-6 is rapidly produced by glial cells during seizure activity 48. 
However, astrocytes are considered the major producers of this cytokine 116. Various studies 
have emphasized the role of this cytokine in the initiation of inflammation, through the 
production of chemokines, cytokines (e.g., IL-1β, TNF-α and IL-6 itself) 119. In relation to 
excitotoxicity and seizure generation, IL-6 has a dual effect that appears to depend on its levels 
in the brain and on the type of cells producing the cytokine, emphasizing the importance of the 
tissue microenvironment 34,116,117. However, the mechanisms underlying the protective or 
destructive effects of this interleukin in neuronal excitotoxicity are not yet completely 
understood 116. Noteworthy, the majority of studies describe IL-6 as a neurotrophic factor, with 
an important role against excitotoxicity-induced neuronal damage 116. 
1.10 Cell death  
The knowledge of molecular pathways underlying neuronal death are considered very 
important in epilepsy 111. Numerous studies performed in both experimental models and in TLE 
patients showed that repeated or prolonged seizures (status epilepticus) can cause neuronal 
death within vulnerable brain regions, such as the hippocampus 111,120. Moreover, evidence 
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proved that cell death is also able to induce seizures 111. The main mechanism of epileptic cell 
damage has been attributed to excitotoxicity, which mainly results from an over-activation of 
ionotropic glutamate receptors, since glutamate is the principal neurotransmitter in the brain 
121. Excitotoxicity is able to provoke cell death by necrosis and apoptosis 122-124. Necrosis and 
apoptosis are two different forms of cell death 125. Necrosis usually occurs when cells are 
injured to the point where they are beyond repair and provokes damage to the surrounded tissue 
126. On the other hand, apoptosis is a physiological process of programmed cell death, meaning 
that, it is cell-autonomous and controlled 124,127, with formation of membrane-enclosed vesicles, 
known as apoptotic bodies 128. In contrast to necrosis, apoptosis does not inflict damage to the 
surrounding tissue and neither induces inflammation 126.  
Caspases, a family of cysteine proteases, are the central regulators of apoptosis. Two major 
caspase-dependent pathways have been described. The intrinsic pathway, considered as the 
most relevant to seizure-induced neuronal death, is activated by several intracellular stressors, 
and ultimately leads to initiator caspases (e.g., caspase-9) activation, which processes the 
downstream effector caspases (e.g., caspase-3, -6, and -7) 120,129-131. The extrinsic caspase 
pathway is activated by cell surface-expression of death receptors of TNF superfamily 132. Upon 
binding to its receptors, TNF recruits intracellular adaptor proteins such as Fas-associated death 
domain protein (FADD) or TNFR associated death domain (TRADD) 133. Then these 
complexes recruit caspase-8 and -10 followed by the cleaving of effector caspases, particularly 
caspase-3 112. Furthermore, there is also a caspase-independent apoptotic pathway 120. In this 
apoptotic-pathway, apoptosis inducing factor (AIF) and calpains seem to be the critical 
mediators. Calpain is a protease that coordinates the calcium-dependent signaling pathways 
underlying neuronal death 134. 
1.11 Experimental Models of epilepsy 
The development and characterization of experimental models has offered an enormous 
contribution to the knowledge of basic cellular, molecular and electrophysiological mechanisms 
of epileptogenesis 135,136. Nevertheless, validated experimental models of epilepsy are essential 
to gain insights into the neural mechanisms of epilepsy, but also to test the efficacy of new 
AEDs and novel therapeutic approaches 137. Given the disadvantages of the in vivo models, 
such as the need for large number of animals, the high mortality, and the relative slow data 
collection, there is an increasing interest in simpler models of epilepsy 138,139. In vitro models 
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allow the application of a more detailed and well-controlled variety of methods that would, 
otherwise, be difficult to employ under in vivo conditions 140, while preserving the critical 
network phenotypic features which generate recurrent seizures 141. However, these seizure 
models lack the behavioural and motor components of clinical seizures 140. Acute brain slices 
are the most popular in vitro preparations. 140. However, it also has several disadvantages. One 
of them is the very short viability of acute slices, which only last for a few hours and unable to 
study chronic epileptogenesis. In contrast, cultures of brain tissue (e.g., organotypic 
hippocampal slice culture) are considered a long-term preparation, maintaining, over time, 
many aspects of the in vivo context, such as the brain architecture and the functional local 
synaptic circuitry 142.  
1.12 OHSC as a model of epileptogenesis  
Over time, the organotypic hippocampal slice cultures (OHSC) have been progressively useful 
and advantageous for the study of several neurobiological disorders, including epilepsy and 
neuroinflammation 143,144. These cultures reproduce and preserve the intrinsic properties and 
the complex in vivo organization of the cellular network 145. Moreover, they can be maintained 
for several weeks in an artificial growth medium allowing to follow long time effects 140.   
There are two studied methods used to prepare slices cultures: the roller tube, pioneered by 
Gähwiler 146 and the membrane interface technique, established by Stoppini and co-workers 147. 
Usually, the cultures of organotypic slices of hippocampus and cortex regions, are prepared 
from 6- to 7-day-old pups (P6-7) 148, since at this age the hippocampal cytoarchiture is already 
established and can then be studied from 7 to 30 days in culture 135.  OHSC are prepared from 
postnatal rats and do not represent adult tissue 135. Only after three weeks in vitro (21 days in 
vitro) 149, the maturation of the different cell types, synaptic contacts and receptor expression 
resembles what is observed in the adult tissue 142,150–152 
The trauma of culturing has a profound effect on the survivability of neurons. A robust 
degeneration of neurons start as early as four hours after culturing and continues up to at least 
6 DIV followed by a low-level of neuronal death that persists up to at least 28 DIV 153. 
Furthermore, the deafferentation that occurs during tissue slicing, leads also to some 
reorganizational processes, which are also observed in chronic epileptic rats 154 and epilepsy 
humans patients 155. These reorganizational processes include: mossy fiber sprouting and 
formation of recurrent excitatory connectivity (also a feature of TLE) and reorganization in 
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CA1 region 156-160. As a consequence of these alterations, excitatory activity progressively 
increases during culture time and epileptogenesis may be initiated  159,161,162. Therefore, OHSCs 
may provide a model of chronically epileptic tissue, since the development of abnormal 
connectivity in the organotypic slices mimics the aberrant connectivity found in the epileptic 
brain 135. Despite these morphological features, spontaneous epileptiform activity without 
pharmacological induction has rarely been reported in OHSC 163. However, recently, some 
groups described in detail the functional characterization of spontaneous development and 
evolution of epileptiform activity within OHSC, which were maintained in an artificial growth 
medium without serum (Neurobasal A supplemented with B-27) 164,165. A high incidence of 
spontaneous epileptiform activity was recorded in OHSCs from 7 to 30 DIV. Other features 
related to TLE, such as the latent period and anticonvulsant resistance, were also reported 141,164.  
Taken together, the electrophysiological and morphological abnormalities described so far 
make the OHSC a simple and powerful system that can allow the study of cellular and molecular 
mechanisms involved in the mechanisms of epileptogenesis. Hopefully, it will bring us one step 
closer toward the development of novel therapeutic approaches.  
2 AIMS 
Research directed toward the therapeutic benefits of anti-inflammatory agents is now 
considered crucial on the ongoing search for novel antiepileptic drugs 167. Targeting 
inflammatory pathways, is regarded as a novel option for the development of biomarkers 168 
and therapies for epilepsy 12. Thus, a full knowledge about the crosstalk between 
neuroinflammation and epileptogenesis is imperative. 
In this work the organotypic hippocampal slice model of epileptogenesis 164 was used in order 
to disclosure the impact of spontaneous epileptiform activity upon inflammation. In order to 
accomplish this, a molecular characterization of inflammatory mediators was carried out. 
Several topics were evaluated throughout culture time, namely: 
 
 Cell death; 
 Astrocytes and microglia activation; 
 Transcript expression of inflammatory cytokines, specifically IL-1β, 
TNF-α and IL-6.   
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3 MATERIALS AND METHODS 
3.1 Animals 
Sprague-Dawley rats were obtained from Charles River (Barcelona, Spain). All the procedures 
were performed according to the European Union guidelines (2010/63/EY) and Portuguese law 
concerning the protection of animals for scientific purposes. All efforts were made to minimize 
animal suffering and to use the minimum number of animals. 
3.2  Organotypic Hippocampal Slice Culture  
In this work, organotypic hippocampal slice cultures were prepared from 6- to 7- days-old 
Sprague-Dawley rats, according to the interface culture method 147. Rats were decapitated, 
brains were removed and placed, under sterile conditions, in cold Gey’s balanced salt solution 
(GBSS) with 25 mM glucose.  
Combined Entorhinal cortex-hippocampi slices were dissected out and sliced transversely at a 
thickness of 350µm using a McIIwain tissue chopper. Five slices were placed onto porous (0.4 
µm) insert membranes (PICM 0305 Millipore, Bedford, MA) and transferred to six-wells 
culture plates (Corning Costar, Corning, NY) (Figure 9 in Appendix, section 9.1). Each well 
was filled with 1mL of medium, containing 50% Opti-MEM, 25% Hank’s balanced salt 
solution, 25% heat inactivated horse serum, 25 mM glucose, 100 units/mL of penicillin and 100 
µg/mL of streptomycin. The culture plates were maintained in an incubator at 37°C in 5.0% 
CO2 and 95% atmospheric air.  
After 3 days in vitro the culture medium was replaced with 1mL of a chemically defined serum-
free medium, Neurobasal A, supplemented with 1mM L-glutamine, 100 units/mL of penicillin 
and 100 µg/mL of streptomycin, 2% B-27 (contains several hormones, fatty acids and free 
radical scavengers 169,170 and decreasing horse-serum concentrations until a serum-free 
condition was reached at 9 DIV (Figure 10 in Appendix section 9.2). Since several amino acids 
are rapidly consumed within 2 days 171 and glutamine spontaneously degrades, generating a 
toxic product (ammonia) 172, Neurobasal A-based medium was changed every second day, for 
three weeks (21 DIV). All experimental assays were carried out at 7, 14 and 21 DIV. 
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3.3  Propidium iodide (PI) uptake assay 
Cell death in OHSCs was evaluated by the cellular uptake of the fluorescent dye propidium 
iodide (PI). Staining in OHSC is simpler because the dye can be added to the culture medium 
140. PI only enters cells with damaged membranes, and when bound to nucleic acids it allows 
to see the damaged cells brightly fluorescent (absorbance at 530nm and emission at 620nm) 173. 
PI is not toxic to cells and has been widely used as an indicator of neuronal membrane integrity 
and cell damage 145. The slices at 7, 14 and 21 DIV were incubated with 2µM sterile propidium 
iodide solution (Sigma, St. Louis, MO, USA) for 4 hours before imaging. Cellular uptake of PI 
was recorded in a widefield fluorescence microscope (Axiovert 200, Zeiss, Germany) using an 
EC Plan-NeoFluar 5x objective, a rhodamine filter and a digital camera. 50 ms exposure time 
was used in all assays. For quantitative assessment of neuronal damage, the regions of interest 
(CA1, CA2/CA3 and DG) were delineated using the software application ImageJ (NIH). The 
intensity value of each analyzed region was obtained by correction with a fluorescence 
background image. This assay does not discriminate between necrosis and apoptosis.   
3.4  Western blot 
3.4.1 Tissue lysates 
In this study, Western blot analysis was performed in order to address expression changes of 
proteins related to cell death and also in glial cell markers. 
Hippocampi were dissected from 4-5 slices and cell lysis were performed in 150 µL of RIPA 
(Ristocetin Induced Platelet Agglutination) buffer containing 50mM Tris pH 8.0, 1mM EDTA 
(Ethykenediamine Tetraacetic Acid), 150mM NaCl, 1% NP40 substitute (Nonyl 
phenoxlpoylethanol, from Fluka Biochemika, Switzerland), 1% SDS (Sodium Dodecyl Sulfate) 
and 10% glycerol. During extraction, protein degradation is prone to occur due to endogenous 
proteases released upon cell disruption. Thereby, RIPA buffer was supplemented with protease 
inhibitors (Complete Mini-EDTA free, Roche, Germany) and 1mM PMSF 
(phenylmethysulfonyl fluoride). Cell suspension was left shaking during 15 min at 4ºC and the 
insolubilized fraction was removed by centrifugation, 11000g for 10 min at 4ºC. Finally, the 
supernatant was collected and stored at -20ºC for further use. 
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Total protein was quantified with the BioRad DC Protein assay Kit, using BSA (Bovine Serum 
Albumin) as standard. Before samples were loaded onto the gel, they were submitted to a 
temperature of 95ºC for 10 min in order to denature the higher order structures, while retaining 
sulfide bridges.   
3.4.2 Western blot assay 
Samples (40μg of protein per lane) and protein size markers (Precision Plus Protein Standars, 
Bio-Rad) were run on a standard 12% SDS-PAGE and electrotransferred onto a PVDF 
membrane (Millipore) at a constant voltage of 150 V for 1h30. 
Membranes were blocked for 1h with 3% BSA in TBS-T (20mM Tris base, 137mM NaCL and 
0.1% Tween-20) at room temperature. Subsequently, membranes were probed with the primary 
antibodies (Table 1 in Appendix section 9.3), diluted in TBS-T with 3% BSA, overnight at 
4°C. Finally, membranes were incubated for 1h at room temperature, with goat anti-rabbit, 
donkey anti-goat or donkey anti-mouse secondary antibody (1:10000, Santa Cruz 
Biotechnology) linked to HRP (Horseradish Peroxidase). Development of signal intensity was 
carried out using ECL Plus Western Blotting Detection System (Amersham-ECL Western 
Blotting Detection Reagents from GE Healthcare, Buckingamshire, UK) and detected using X-
Ray film (Fujifilm). The relative expression of the protein bands was accomplished with Image 
J software and standardized for GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) levels. 
Protein levels at 14 and 21 DIV were normalized to 7 DIV levels.  
3.5  qPCR 
3.5.1 RNA isolation and quantification 
RNA was extracted from OHSCs according to QIAGEN RNeasy Mini Kit (Qiagen). Slices, 
were defrosted in 1ml of QIAzol Lysis reagent with a TissueRuptor homogenizer, previously 
DEPC-treated.  Quantification of total RNA was accurately determined using Nanodrop 1000 
(ND-1000 Spectrophotometer, Thermo Scientific). 
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3.5.2 Reverse Transcription reaction 
Two reaction mixes were prepared to perform the in vitro reverse transcription (RT) reaction: 
1) RNA mix containing 2 µg of total RNA, 1 µL of random primers and 1 µL dNTPs, in a total 
volume of 10 µl; 2) SuperScript mix containing 25 mM MgCl2, 0.1M DTT (Dithiothreitol) and 
SuperScript II reverse transcriptase buffer in a total volume of 10 µl. RT-PCR was carried out 
in a thermoclycler (MyCycler – Bio-Rad, Hercules, CA 94547).  
First RNA was heated for 5 min at 65 ºC and chilled for 2 min at 4ºC, followed by the addition 
of the SuperScript mix. When temperature reached 25 ºC, 50 units of SuperScript II Reverse 
transcriptase (EC 2.7.7.49, Invitrogen, Carlsband, CA, USA) was added followed by 60 min at 
42 ºC (optimal SuperScript II temperature). Reaction was terminated by inactivating the 
enzyme for 20 min at 72 ºC.  
For each RNA sample a reverse transcription reaction was carried out in the absence of reverse 
transcriptase in order to ensure that product amplification did not arise from genomic DNA. 
3.5.3 Relative quantification 
cDNA amplification was performed in a Rotor-Gene 6000 real-time rotary analyzer 
thermocycler (Corbett Life Science, Hilden, Germany) in the presence of SYBR Green Master 
Mix (Applied Biosystems, Foster City, CA, USA) and 0.2 µM of each specific gene primer 
(Table 3 in Appendix section 9.4). The amplification of cDNA was carried out by the following 
program: an initial denaturation for 2 min at 95ºC, 50 cycles with 30s at 94ºC, 90s at 60ºC and 
60s at 72ºC, followed by a melting curve to assess the specificity of the reactions. The Ct (Cycle 
Threshold) and the melting curves (panels C of Figures 14-21) were acquired with Rotor-gene 
6000 Software 1.7 (Corbett life Science). In order to determinate the PCR efficiency (E) for 
each gene, which is needed for relative quantification by comparative Pfaffl method, a qPCR 
with cDNA samples from 5-fold sequential dilutions of cDNA was performed for each set of 
primers. In all experiments GAPDH was used as a reference internal gene. For each gene, 
replica reactions were performed and the mean of two reactions was used to calculate the 
corresponding expression level. Two types of negative controls were run with samples, 1) no 
reverse transcription control, which used cDNA obtained in the absence of SuperScript II and 
2) no template control, which did not contain cDNA. 
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3.6 Gel electrophoresis 
The electrophoresis was performed in a 2% agarose gel in TAE buffer (Tris-acetate-EDTA: 
20mM glacial acetic acid, 40 mM Tris base and 1 mM EDTA) with 0.05 µL of GelRed 
(Invitrogen, Biotechnology) per 1 mL of TAE. After amplification in Rotor-gene 6000, 15µL 
of each PCR product plus 3µL of loading buffer (6x NZYDNA loading dye, Nzytech) were 
loaded on the agarose gel. Molecular weights of cDNA were assessed by running, alongside, a 
marker for DNA size (5 µl) (NZYDNA Ladder V, Nzytech). 
3.7 Immunohistochemistry (IHC) 
3.7.1 Immunohistochemistry 
Slices were fixed for 1h with 4% paraformaldehyde (PFA) diluted in phosphate-buffer solution 
(PBS) at room temperature, followed by an incubation in increasing concentrations of  a sucrose 
solution (10% and 20% in PBS) at room temperature and lastly slices were kept in 30% sucrose 
solution at 4ºC until further use.  
Slices were cut out of the insert and put in slides (2 slices per slide). Each slice was surrounded 
with DAKO pen (Dako, Denmark) to protect staining areas from drying out and from mixing 
with each other. Followed PBS washes, slices were incubated for 3h at room temperature in 
blocking solution containing 10% BSA 10% Horse Serum and 1% Triton X-100 in PBS, which 
ensure simultaneous blocking and permeabilization of the tissue. Subsequently, slices were 
incubated with the primary antibodies (Table 2 in Appendix section 9.3) diluted in blocking 
solution for 48h at 4ºC. Slices were rinsed with PBST (PBS containing 0.1% Tween-20) and 
the secondary antibodies, coupled to fluorophores (donkey anti-rabbit Alexa Fluor 488, donkey 
anti-goat Alexa Fluor 488 or donkey anti-mouse Alexa Fluor 568, 1:400, Invitrogen), were 
applied to the slices for 24h at room temperature. The nuclei were stained with Hoechst 33342 
(1:100 dilution in PBS from a 2mg/mL stock; Invitrogen) for 40 min at room temperature and 
then washed. The coverslips were mounted in Mowiol (40 µL per slice), which is a non-
absorbing compound without autofluorescence and light scattering, and is, therefore, 
considered adequate for fluorescence microscopy. Finally, slices were imaged with a confocal 
laser scanning microscope (LSM 710, Zeiss, Germany), using an EC plan-NeoFluar 5x to obtain 
images of the whole hippocampus and a Plan-Apochromat 20x objective (Zeiss, Germany) to 
achieve specifically images from DG, CA3 and CA1 regions.  
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4 RESULTS 
4.1  Cell death 
As already mentioned, cell death and neuroinflammation are closely associated 27,124. In order 
to characterize cell death in the OHSC model of epileptogenesis an evaluation by PI uptake and 
αII-Spectrin cleavage was carried out. Assays were performed at 7, 14 and 21 DIV. 
4.1.1  PI uptake 
PI uptake in DG, CA3 and CA1 regions of organotypic slices was measured. The three analyzed 
time points show PI-positive cells in all regions of the hippocampus (Figure 1A), which 
corroborates the occurrence of cell death. The lower PI uptake was observed at 7 DIV slices, 
while the maximum cell death occurred at 14 DIV slices (Figure 1B). When comparing 7 and 
14 DIV slices, all regions show a significantly higher level of PI uptake in 14 DIV slices (DG: 
33.39 ± 4.13 vs 107.1 ± 9.86; CA3: 22.59 ± 2.89 vs 133.1 ± 9.79; CA1: 59.16 ± 4.07 vs 160.2 
± 11.90, ***p<0.001) (Figure 1B). Regarding 14 and 21 DIV slices, CA3 (133.1 ± 9.79 vs 
54.24 ± 10.04, **p<0.01) and CA1 regions (160.2 ± 11.90 vs 98.69 ± 9.63, *p<0.05), show a 
significant decrease of PI uptake in 21 DIV slices (Figure 1B). In DG, a significant increase in 
PI uptake was observed from 7 to 14 DIV slices, as pointed out above, while no differences 
were obtained between 14 and 21 DIV slices (107.1 ± 9.86 vs 101.0 ± 14.96, p>0.05) (Figure 
1B). Overall, the CA1 was the region that suffered the highest cellular damage at all three 
evaluated time points (Figure 1B).  
 
4.1.2 αII-Spectrin cleavage 
Characterization of cell death was also assessed through the evaluation of αII-Spectrin cleavage 
and Pro-caspase-3 activation by a western blot assay, carried out with protein extracts obtained 
from the hippocampal region of the slices.  
αII-Spectrin is a structural protein of the cell membrane cytoskeleton, being important for 
membrane stability and cell shape regulation 174. This cytoskeleton protein is abundant in 
neurons of the CNS and plays vital roles in neuronal support and synaptic plasticity 175. In its 
simplest form, spectrin has a molecular weight of a 250 kDa and it is a major substrate of 
calcium-dependent proteases, such as calpain and caspase-3. Calpain is involved in necrotic 
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and apoptotic cell death, while caspase is only activated in apoptosis 176. Thereby, events as 
neuronal death and stress or injury, which enhance proteolysis, lead to an increase of spectrin 
break down products (SBDP) 175. There is a unique calpain mediated fragment with a molecular 
weight of 145 kDa (SBDP 145). Caspase-3 mediated alpha II-Spectrin cleavage leads to the 
formation of SBDP 150, which has 150 kDa. In addition, this product can be further degraded 
by caspase-3, producing the apoptotic-specific 120 kDa fragment 176. For this reason, recent 
works use the SBDP as a potential biochemical marker of cell death in neurodegenerative 
disorders 177,178. Since αII-spectrin presence in glial cells is minimal, the SBDP are highly 
specific for neuronal damaged 174. The three referenced spectrin breakdown products can be 
detected by antibodies against αII-spectrin 175, allowing to discriminate which type of cell death 
process is occurring in OHSC, throughout time in culture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1| Propidium iodide (PI) uptake in OHSC. A) Representative photomicrograph depicting PI staining show differences 
in cell death between DG, CA3 and CA1 regions of hippocampus throughout time in culture. B) Quantification of PI uptake in 
each hippocampal region expressed in arbitrary units of fluorescence intensity. All values are mean ± SEM. 9 < slices <30; 
*p<0.05, **p<0.01, p***<0.001, one way ANOVA followed by Bonferroni’s Comparison Test. 
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Figure 2| Western blot analysis of alpha-II Spectrin and Caspase-3. A) Representative immunoblots of αII Spectrin and 
Caspase-3 at 7, 14 and 21 DIV. Lane Aβ, which contains a sample of primary neuronal cultures incubated with Aβ, was used 
as a positive control of αII Spectrin cleavage and of caspase-3 activated form. GAPDH was used as the loading control. 
Densitometry analysis of αII-Spectrin (B), SBDP 145/150 (C) and pro-caspase 3 (D) performed with ImageJ software. All 
values are mean ± SEM. N=4-8; *p<0.05, one way ANOVA followed by Bonferroni’s Comparison Test. 
In the three time points studied, full-length αII-spectrin (250 kDa) was detected by western blot 
analysis (Figure 2A). In relation to 7 DIV, a tendency for decreased expression was observed, 
but with no statistical significance (7 DIV: 1.083 ± 0.0866; 14 DIV: 0.9717 ± 0.08923 and 21 
DIV: 0.7771 ± 0.05018; p>0.05) (Figure 2B). The expression of SBDP 150 and SBDP 145 was 
not possible to visualize separately (Figure 2A), and since the 120 kDa SBDP, which resulted 
from the caspase-3 cleavage of αII-spectrin, was absent from all times points, the band 
visualized at approximately 150 kDa corresponds solely to the calpain-mediated fragment of 
spectrin (SBDP 145). The expression of SBDP 145 increased significantly from 7 to 14 DIV 
slices (7 DIV: 1.000 ± 0.1648 vs 14 DIV: 1.685 ± 0.1304, *p<0.05), but no further differences 
in cell death were obtained from 14 DIV on (14 DIV: 1.685 ± 0.1304 vs 21 DIV: 1.303 ± 
0.1841, p>0.05) (Figure 2C).  
Regarding the caspase-3 immunoblot, a tendency for decreased pro-caspase-3 expression (32 
kDa) was detected at 14 DIV (0.7425 ± 0.1209) and at 21 DIV slices (0.6700 ± 0.0723), when 
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compared to 7 DIV slices (0.9983 ± 0.1298, n=6) (Figures 2A and 2D). However, the band 
corresponding to the active caspase-3 form (17 kDa) was absent in all time points. In order to 
prove the proper antibody staining, a positive control (lane Aβ), which contain a lysate from a 
primary neuronal culture treated with Aβ 179, was loaded into the gel. As depicted in Figure 
2A, this sample shows the presence of SBDP 120 and of the 17 kDa band of active caspase-3. 
Altogether, these results indicate that the pro-caspase-3 was progressively cleaved but not by 
an initiator caspase and thus, does not originates the active caspase-3. These results also 
corroborate the detection of αII-spectrin break down products originated by calpain cleavage 
only and not by caspase-3 cleavage, and point to the occurrence of cell death by necrosis or 
through the caspase-independent apoptotic pathway. 
4.2 Astrogliosis and microglia activation 
Reactive gliosis is considered as a major hallmark encountered both in neuroinflammation and 
in temporal lobe epilepsy 13,41–43. Therefore, the astrocytic and microglial activation was 
evaluated in the OHSC model of epileptogenesis. Glial fribrillary acidic protein (GFAP) is an 
intermediate filament protein (with cyto-architectural function), expressed specifically in 
astrocytes. For this reason, GFAP expression has become an astrocytic marker 82. Moreover, an 
increased expression of this protein represents the activation of astrocytes 180. Ionized calcium-
binding molecule 1 (Iba-1) is a protein with a localization restricted to microglia 181,182, thus 
being used as a microglia-specific marker. Calcium-binding protein expression level increases 
upon microglia activation 182 and it has proven to be helpful in visualizing microglia 
morphology 183.  Astrocytes and microglia were evaluated through GFAP and Iba-1 expression, 
respectively, by western blot analysis and by immunohistochemistry assays. The western blot 
assay was used to evaluate the expression level, while immunofluorescence assay allowed to 
assess astrocytes and microglia morphology within time in culture. 
4.2.1 Analysis by western blot 
Although a tendency for increased GFAP protein expression from 7 to 21 DIV was observed 
(Figures 3A and 3B), no significant differences (p>0.05) were achieved between 7 (1.076 ± 
0.1135), 14 (1.157 ± 0.0785) and 21 DIV slices (1.263 ± 0.07632). Regarding Iba-1 protein 
expression (Figure 3A), a significant decrease was found in both 14 DIV (0.6240 ± 0.0565, 
*p<0.05) and 21 DIV slices (0.6075 ± 0.0584, *p<0.05) when comparing with 7 DIV slices 
(1.000 ± 0.1388) (Figure 3C). 
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Figure 3| Western blot analysis of GFAP and Iba-1. A) Representative immunoblots of GFAP and Iba-1. GAPDH was used 
as the loading control. Densitometry analysis of GFAP (B) and Iba-1 (C) performed with ImageJ software. All values are mean 
± SEM. N=6-10, *p<0.05, one way ANOVA followed by Bonferroni’s Comparison Test. Statistical tests were performed in 
comparison with 7 days DIV slices. 
4.3 Analysis by immunofluorescence 
The following panels depict the immunofluorescence images obtained by the double detection 
of Hoechst, together with GFAP (Figure 4) and Iba-1 (Figure 5). An evaluation of glia 
morphology changes throughout time was performed in DG, CA3 and CA1 regions of the 
hippocampus. The specific areas where the images were taken are delineated by the dotted line 
drawn in the image of the whole hippocampus. 
4.3.1 Astrocyte activation 
GFAP staining at 7 DIV showed a vast number of astrocytes with long and overlapping 
processes covering the DG and CA3 regions (Figures 4A2 and 4A3), resembling a reactive 
astrocytic scar, as already described 67,82,184. In CA1 region (Figure A4), the morphology 
characteristic of moderate reactive astrocytes, the hypertrophic cell body with numerous 
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interdigitated processes, only within individual domain of each astrocyte, can be observed. The 
astrocytic scar is not yet defined in this region. As the culture time extended, astrocytic 
processes became longer and ticker in this region. From 14 DIV on, all regions of the 
hippocampus are covered with astrocytic overlapping processes, which form a dense glial scar 
(Figures 4B2-4 and 4C2-4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4| Astrocytes activation in organotypic slices at 7, 14 and 21 days in vitro (DIV). Detection of Hoechst stained 
nucleus (blue), together with GFAP stained astrocytes (green). Confocal images were obtained with a 5x objective (A1, B1 and 
C1) and a 20x objective (A2-4, B2-4 and C2-4). The dotted lines delineate the magnified regions. Scale bar, 200µm.  
 
4.3.2 Microglia activation 
Regarding microglia, western blot results point to a significant decrease of Iba-1 
immunoreactivity throughout time. This decrease is corroborated by the immunofluorescence 
assay in the images of the whole hippocampus (Figures 5A1, 5B1 and 5C1) and it can be 
associated with differences in the activation state of microglia cells. At 7 DIV, microglia cells 
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demonstrate small cell bodies with extensive and thin ramifications in the DG region (Figure 
5A2), while in CA3 and CA1 regions, microglia displays an amoeboid like morphology with 
shorter and thicker branches, consistent with an active state (Figures 5A3 and 5A4). 
Concerning microglia morphology at 14 DIV slices, microglia displays a “reactive” form with 
rounder and larger cell bodies in DG layer, denoting their amoeboid phenotype (Figure 5B2). 
This activated state was not observed in the pyramidal cell region. In fact, when comparing 
with 7 DIV slices, the microglia in the CA3 and CA1 areas show a reversion to a primed 
morphology, having an increase of their distal ramifications (Figures 5B3 and 5B4). At the last 
studied time point, the majority of microglia cell population displays a resting ramified 
morphology with small cell bodies and numerous thin processes (Figures 5C2-4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5| Microglia activation in organotypic slices at 7, 14 and 21 days in vitro (DIV). Detection of Hoechst stained 
nucleus (blue), together with Iba-1 stained microglia (green). Confocal images were obtained with 5x objective (A1, B1 and 
C1) and a 20x objective (A2-4, B2-4 and C2-4). The dotted lines delineate the magnified regions. Scale bar, 200µm. 
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4.4 Inflammatory mediators 
Interleukins IL-1β and IL-6, as well as tumor necrosis factor-α (TNF-α), are pointed out as the 
principal pro-inflammatory cytokines involved in epilepsy. Their expression was found to occur 
mainly in glial cells 92.  
4.4.1 qPCR 
This chapter addresses the transcript expression of these cytokines and their respective receptors 
by qPCR. This assay was performed in samples obtained from organotypic hippocampal slices 
with 7, 14 and 21 DIV and used specific oligonucleotide primers as detailed in Table 3 (in 
Appendix, section 9.4).  
4.4.1.1 IL-1β 
The transcript analysis of interleukin-1β and IL-1RI showed an increase throughout time in 
culture (Figure 6). In 14 DIV slices, IL-1β increased by 2.240 ± 0.4769 fold, without statistical 
significance (p>0.05) when compared to 7 DIV slices (0.8633 ± 0.2267) (Figure 6A). A much 
higher expression of IL-1β transcript was obtained at 21 DIV with a significant increase of 
3.943 ± 0.7372 fold (*p<0.05) compared to 7 DIV (Figure 6A). Regarding IL-1RI mRNA 
expression, Figure 6B shows a minor increase from 7 DIV to 14 DIV (0.9433 ± 0.1875 vs 
1.125 ±0.1051, p>0.05). The increase in mRNA expression became significant at 21 DIV, when 
compared to the first time point studied (1.813 ± 0.2022, *p<0.05).  
 
 
 
 
 
 
 
 
 
 
Figure 6| Transcript expression profile of interleukin-1β (IL-1β) and its receptor ILR1. Evaluation of IL-1β (A) and 
ILR1 (B) mRNA in slices at 7, 14 and 21 DIV, by relative qPCR. All values are mean ± SEM. *p<0.05, N=3-4, one way 
ANOVA followed by Bonferroni’s Comparison Test. Statistical tests were performed in comparison with 7 DIV slices. 
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4.4.1.2 TNF 
TNF-α mRNA levels has also shown an enhancement throughout time in culture (Figure 7A). 
When comparing with 7 DIV slices (1.050 ± 0.1867), TNF-α mRNA levels increased by 1.983 
± 0.0533 fold in 14 DIV slices, but without statistical significance (p>0.05) (Figure 7A). A 
much higher expression enhancement was obtained in 21 DIV slices (4.886 ± 0.7347, 
**p<0.01) (Figure 7A). The increase in mRNA expression was also significant between 14 
DIV and 21 DIV (*p<0.05) (Figure 7A). Regarding both receptors of this cytokine, an mRNA 
enhancement throughout culture time was only found in TNFR2 (Figure 7C). However, 
significant difference was only obtain when comparing 7 DIV with 21 DIV slices (7 DIV: 
0.8267 ± 0.1445 vs 21DIV: 2.450 ± 0.5103, **p<0.01) (Figure 7C). The 14 DIV slices solely 
achieved an increase of 1.307 ± 0.1218 fold for TNFR2 with statistical significance when 
compared to 21 DIV slices (*p<0.05) (Figure 7C). The TNFR1 did not show any differences 
in transcription levels throughout time (7 DIV: 1.008 ± 0.0700; 14 DIV: 1.060 ± 0.0994 and 21 
DIV: 1.350 ± 0.2411) (Figure 7B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7| Transcript expression profiles of Tumor necrosis factor alpha (TNF-α) and its receptors (TNFR1 and TNFR2). 
Evaluation of TNF-α (A), TNFR1 (B) and TNFR2 (C) mRNA in slices at 7, 14 and 21 DIV by relative qPCR. All values are 
mean ± SEM. *p<0.05, **p<0.01, N=3-6, one way ANOVA followed by Bonferroni’s Comparison Test. Statistical tests were 
performed in comparison with 7 DIV slices, except if otherwise indicated by the line above the bars. 
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4.4.1.3 IL-6 
Transcript expression of IL-6 did not show a significant difference when comparing 7 with 14 
DIV slices (1.043 ± 0.1586 vs 1.127 ± 0.2085, p>0.05) (Figure 8A). In contrast, a significant 
enhancement of 3.514 ± 0.0556 fold in 21 DIV slices was achieved, with a statistical 
significance of **p<0.01 and *p<0.05 when compared to 7 DIV and 14 DIV slices, respectively 
(Figure 8A). Lastly, IL-6 receptor mRNA levels reached a significant increase (*p<0.05) at 21 
DIV (3.213 ± 0.6573), when compared with 7 DIV (0.7467 ± 0.2019) and with 14 DIV slices 
(1.168 ± 0.2659) (Figure 8B). IL-6R mRNA level did not increase from 7 to 14 DIV.  
 
 
 
 
 
 
 
 
Figure 8| Transcript expression profiles of interleukin-6 (IL-6) and the receptor IL-6R. Evaluation of IL-6 (A) and IL-6R 
(B) mRNA in slices at 7, 14 and 21 DIV by relative qPCR All values are mean ± SEM. *<p0.05, **p<0,01, N=3-5, one way 
ANOVA followed by Bonferroni’s Comparison Test. Statistical tests were performed in comparison with 7 DIV slices, except 
if otherwise indicated by the line above the bars.  
 
5 DISCUSSION 
5.1 OHSC as a Model of Epileptogenesis 
The study of epileptogenesis is important to gain knowledge about the mechanisms involved in 
the progression of epilepsy and, ultimately, to acquire new and more efficient therapeutic 
approaches. Organotypic hippocampal slice cultures share common features with TLE. Also, 
several features of other experimental models of epileptogenesis are recapitulated in this model, 
such as the development of abnormal connectivity, the latent period, ictal and interictal activity 
that underlie the onset of spontaneous seizures, clustering of seizure activity and the 
development of anticonvulsant resistance 135,185–187. Noteworthy, all these features are in a 
compressed time scale, which make the organotypic cultures a less time consuming - low cost 
model system of epileptogenesis 164. Therefore, the aim of this project was to use the OHSC to 
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address the inflammatory progression throughout the course of epileptogenesis, specifically cell 
death, activation of astrocytes and microglia and expression of inflammatory mediators 
140,188,189. 
5.2 Cell death 
Seizures can be damaging to the brain, particularly if seizures are prolonged (status epilepticus) 
or repeatedly evoked, leading to neuronal loss in vulnerable brain regions, such as the 
hippocampus. However, it is important to highlight that the severity of hippocampal cell death 
is not proportional to the number of seizures or the duration of epilepsy 190. Excitotoxicity is 
the main mechanism of seizure-induced neuronal death and it is triggered by the intensive 
stimulation of excitatory receptors that leads to an uncontrolled overflow of calcium into the 
neurons, inducing an excitatory response and activation of cytosolic proteases (e.g., calpains 
and caspases) that participate in cell death signaling pathways 91,175,191-193.  
Cell death in hippocampus of TLE patients and in animal models of epilepsy is 
characteristically asymmetric, being CA1 and DG the most affected regions 24,192. In fact, the 
PI uptake assay, in OHSC, was solely confined to the pyramidal and granule cell layers of the 
hippocampus, which suggests that the majority of dying cells were neurons 111,165. The majority 
of cell death was observed in CA1 and it can be associated with the hyperexcitability of neurons 
and with the effect of sprouting of recurrent CA1 axon collaterals 193. Moreover, CA1 region 
has the highest NMDA receptor concentration, therefore excitotoxicity may also be the cause 
of most cell loss in this hippocampal subfield 194,195. Furthermore, glial cells release several 
cytokines that influence cell death (see explanation below) 111. Regarding cell death progression 
in OHSC, a peak of cell damage at 14 DIV in both pyramidal and granule layers was observed. 
This peak of cell death, indicated by PI uptake assay, is in agreement with the highest expression 
of SBDP 145, a excitotoxic marker, obtained by western blot 174.  Previous work by the group 
has shown the occurrence of interictal activity at 14 DIV slices, which corresponds to the cell 
death peak. These results correlate with Staley’s group reports in which cell death, at that time 
point, also coincided with the peak of seizure-like activity and was abolished through blockade 
of glutamatergic transmission or through inhibition of ictal activity 165. Thereby, we also 
propose that the cell death peak observed at 14 DIV is a consequence of spontaneous, post-
traumatic epileptiform discharges that begins to occur at this time 165. With the exception of DG 
region, both PI uptake and SBDP 145 expression decreased at 21 DIV. The decrease of cell 
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death at 21 DIV could be related to the increase of anti-apoptotic cell death signaling induced 
by TNFR2 (see discussion of inflammatory cytokines). Over-expression and cleavage of 
caspase-3 have been found in hippocampal tissue from TLE patients 111,120. But surprisingly, 
no expression of SBDP 120 and caspase-3 active form were obtained at any of the three time 
points analyzed. There is evidence of a cross-talk between the calpain and the caspase pathways, 
in which calpain acts upstream caspases. This means that calpain is able to cleave caspase-3, as 
well as other caspases at non-canonical sites, inhibiting and inactivating this caspase 196. This 
may be a potential explanation for the non-activation of caspase-3 in OHSC. Fujiwaka’s group 
also did not detect any expression of caspase-3 active form in a status epilepticus model 197. 
Other researchers have shown the activation of caspase-3 only several days or even a week after 
status epilepticus in animal models 198,199. The caspase-3 takes part in caspase-dependent 
apoptotic pathways, while calpain is involved in both necrosis and apoptosis 176. Thereby, cell 
death seems mainly to occur either through necrosis and/or through the caspase-independent 
apoptosis pathway, being both cell death processes linked to excitotoxicity 124.  
5.3  Astrogliosis and microglia activation 
Experimental evidence of glia-mediated excitation and inflammation, in promoting the 
precipitation and the recurrence of seizures, has risen during the last decade 48,200,201. In the 
OHSC model of epileptogenesis a tendency for increased GFAP protein expression was 
observed throughout time. IF assay demonstrated a scar-like layer formation over the slice, 
resembling Coltman’s group description 184. This glial scar is essential for spatial and temporal 
restriction of inflammation and damaged tissue and it is mainly formed by reactive astrocytes 
13,202. In our study, at 7 DIV this scar was evident in DG and CA3, while in CA1 it peaked at 
14 DIV. Since mossy fiber sprouting induces an excitatory feedback network 16,23,24,136, we 
suggest that it is likely to be the cause of the scar appearance at DG region. Also, the scar 
formation in CA1 subfield at 14 DIV slices coincided with the highest neuronal loss in OHSC 
and, as a matter of fact, denser astrogliosis was already described to be associated with regions 
where prominent neuronal death occurs 45. A profound “reorganization of glia” was described 
in organotypic cultures due to the trauma of culturing, in which these cells suffer a change in 
morphology, function and proliferation 203. Additionally, At 21 DIV the astrocytic scar covers 
all regions of the hippocampus.  
Regarding microglia activation, Iba-1 expression shows a decrease of about 40% at 14 and 21 
DIV slices when compared to slices with 7 DIV. This decrease was also possible to be 
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demonstrated in the whole hippocampus images obtained through IF assay. Moreover, the 
activated state of microglia was observed in CA1 and CA3 regions at 7 DIV, while this state 
was only obtained at 14 DIV slices in DG region. In slices with 21 DIV, the microglia regains 
its resting state. According to the literature, this activated state remains during the first week of 
culture and coincides with the cell death caused by the culturing process 204,205. Microglia 
converts to an active amoeboid morphology and acts as phagocytic cells in order to clear the 
debris of damaged cells which resulted from culturing 206. Therefore, the functions of microglia 
in OHSC seem to be essential in the regulation of the degenerative responses resulted from the 
trauma of culturing, which is important for synaptic reorganization and repair 207.  
5.4 Inflammatory mediators 
Cytokines are quickly overexpressed followed CNS insults (e.g., seizures) 27 and, consequently, 
these inflammatory mediators alter neuronal excitability and decrease the seizures threshold, 
contributing to epileptogenesis (Foresti, Arisi, & Shapiro, 2010) 37. However, the specific 
mechanisms by which seizure activity induces cytokine production and release in glia cells are 
still unclear. Cytokines can also induce excitotoxicity and apoptotic neuronal death 47,89,90. This 
suggests that the release of cytokines by glia cells during seizures may contribute to seizure-
mediated neuronal damage 52. This hypothesis is supported by several evidences. For example, 
in respect to glutamate, IL-1β and TNF-α inhibit the astrocytic glutamate reuptake, 
subsequently leading to increased glutamatergic neurotransmission 53,208. These two cytokines 
can also contribute to neuronal excitability through alterations in glutamate ionic receptor 
(AMPA) subunit expression 209, turning this receptor calcium permeable 210,211. As a matter of 
fact, the IL-1β and TNF-α effect on the exacerbation in excitotoxic neuronal damage, induced 
by AMPA, was already demonstrated in OHSC 212. Regarding NMDA receptors, IL-1β 
enhances calcium influx into neurons through these glutamate receptors 213,214. In addition, IL-
1β and TNF-α reduce the GABA-mediated inhibition through a decrease in chloride currents 
mediated by this neurotransmitter or by a modification in GABAA receptor 
27,215,216. Moreover, 
TNF-α decreases GABAA-mediated inhibitory synaptic strength, inducing endocytosis of 
GABAA receptors 
217,218. TNF-α signaling represents the major mechanism of apoptotic cell 
death 30. A constitutive expression of TNF death receptors in both astrocytes and microglia in 
human TLE was already documented 219,220. It is important to highlight that cytokines effects 
on threshold frequency and duration of seizures are independent of cell death 211.  
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The OHSC model of epileptogenesis is not an exception and an increase of transcript expression 
of the principal cytokines associated with neuroinflammation events in epilepsy, such as the IL-
1β, IL-6 and TNF-α 49,92, was observed throughout time in culture. However, significant 
differences were only achieved in 21 DIV slices when compared to 7 DIV slices. The mRNA 
expression of IL-6 did not increase throughout time, only reached a peak at 21 DIV. Since 
excitotoxicity is a potent inducer of IL-6 expression 116, IL-6 upregulation might be related with 
the induction of excitotoxicity, through IL-1β and TNF-α effects on glutamate and GABA 
neurotransmission. IL-6 has probably a neuroprotective effect in 21 DIV slices, diminishing the 
neuronal damage that was obtained at that time point 116. Concerning the receptor’s transcript 
expression, a significant upregulation was also solely achieved in slices with 21 DIV for IL-
1RI, TNFR2 and for IL-6R. Studies using animal models of epilepsy, revealed a neuroprotective 
effect of TNF-α, mainly through the binding to TNFR2 114,221, which indicates that TNF-α could 
be playing a role against cell damage at 21 DIV. Thus, this result may also explain the decrease 
of cell death obtained at this time point. IL-1β receptor type I transcript expression is 
significantly increased at 21 DIV slices, which is in agreement with the upregulation of the IL-
1β /IL-1RI described in experimental models of TLE during epileptogenesis 11,51.  
The protein expression evaluation of each cytokine was also attempted in this project. However 
the antibodies used (antibody against TNF-α from NovusBio (1:200) and antibody against IL-
1β from Abcam (1:200)) in the western blot assays were very unspecific. For this reason, ELISA 
assays to evaluate study the amount of protein, in tissue and culture supernatant, are already in 
course. Also, IL-1β and TNF-α expression in glial cells was also attempted through 
immunohistochemistry assay. Double-staining of organotypic slices with GFAP/Iba1 and IL-
1β show an exclusive expression of this cytokine in astrocytes at 21 DIV (Figure 11 in 
Appendix section 9.5). These results are in accordance with other epileptogenesis models, in 
which a quick enhance of IL-1β was detected in both activated microglia and astrocytes, during 
acute seizures 104. After seizure decrease, IL-1β expression did not return to the basal level and 
it persisted during epileptogenesis and in chronic epileptic tissue, being expressed in astrocytes 
and not in microglia 103,104. These findings indicate that microglia act mostly as a source of 
cytokines at the onset of seizures, while astrocytes seem to be involved in the perpetuation of 
inflammation 104. These features were already confirmed in human TLE tissue 51. In fact, in 
contrast to astrocytes, microglia are extremely sensitive and quickly respond to small changes 
in the CNS 81 and microglia-secreted cytokines have been suggested to contribute to the 
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subsequent activation of astrocytes 222. In summary, astrogliosis and microglia activation occurs 
at a different stage 51,223, like was observed in our model of epileptogenesis. 
 
6 CONCLUSION AND FUTURE PERSPECTIVES 
Our results point to an activity dependent inflammation progress, since at 21 DIV, when slices 
depict mixed interictal and ictal-like discharges, a significant upregulation of inflammatory 
mediators was observed in the OHSC model of epileptogenesis. Moreover, at 21 DIV only 
astrogliosis was found, while microglia reversed from an active amoeboid state to a resting state 
throughout time. Therefore, our data point to astrocytes as the major glial cells involved in the 
progression of the inflammatory process in this model. In fact, it has been reported that 
astrogliosis is an underlying component of the neuropathology of epilepsy 224,225. Moreover, 
several studies demonstrated that microglia activation precedes astrogliosis and it is involved 
in its onset, which is in accordance with our results 226. Altogether, the OHSC model of 
epileptogenesis can be considered a useful and simple model to decipher the specific roles and 
functions of glial cells and inflammation in epileptogenesis, seizure initiation and seizure 
spread. 
In the future, we would like to better characterize the expression of IL-1β, IL-6 and TNF-α. We 
aim to evaluate total protein expression and release by ELISA assays, and further disclosure 
their expression in each cell type, by immunofluorescence assays. The pattern of expression of 
cytokine receptors is also important to determine the target cells of the cytokines’ effects 39. A 
study of anti-inflammatory cytokines will also be conducted, since the balance between pro- 
and anti-inflammatory cytokines is crucial for the development of inflammation 30.  
The reduction of seizures through some anti-inflammatory treatments was already 
demonstrated in both experimental models and in clinical cases 34,45. This model will be used 
to explore the effects, upon epileptogenesis, of targeting specific inflammatory pathways. With 
these studies we hope to provide new insights into the mechanisms of epileptogenesis and its 
interplay with inflammatory events and ultimately, contribute to novel pharmacologic strategies 
to arrest epilepsy onset and/or progression. 
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8. APPENDIX 
8.1    Preparation of OHSC 
 
 
 
 
 
 
 
 
 
 
Figure 9 | Preparation of organotypic hippocampal slice cultures.  First the hippocampus and part of entorhinal cortex are 
dissected out from the neonatal brain. The sections are sliced using a tissue chopper, under aseptic conditions, and five slices 
are placed on a membrane insert in a 6-multiwell dish. Cultures are maintained in a CO2 incubator (adapted from Heinemann 
et al., 2006). 
 
8.2    OHSC maintenance 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 | Schematic representation of the OHSC maintenance. OHSCs were kept in Opti-MEM based medium with 25% 
of horse serum (HS) until 3 days. Started at 3 DIV, the medium was changed every second day with Neurobasal A 
(supplemented with 2% B27, 1mM L-glutamine and antibiotics) in the presence of decreasing concentrations of HS (15%, 10% 
and 5%), until complete serum-free medium was reached at 9 DIV. Slices were collected at 7, 14 and 21 DIV to perform 
western blot, qPCR and immunofluorescence assays. For PI assay the slices were incubated with PI solution diluted in culture 
medium for 4 hours before imaging. DIV, days in vitro; HS, horse serum; NA, Neurobasal A. 
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GAPDH – Glyceraldehyde-3-phosphate dehydrogenase adaptor molecule 1; IL-1β – Interleukin-1 beta; IL-1RI – Interleukin-1 
receptor type I; IL-1RII – Interleukin 1 receptor type II; TNF-α – Tumor necrosis factor alpha; TNFR1 – Tumor necrosis factor 
receptor type I;  TNFR2 – Tumor necrosis factor receptor type II;  IL-6 – Interleukin-6; IL-6R – Interleukin-6 receptor 
 
8.3    Primary antibodies  
Table 1 | Primary antibodies used in Western Blot (WB) 
Protein Supplier Host Dilution 
α-II Spectrin Santa Cruz Biotechnology Mouse monoclonal antibody 1:500 
Caspase-3 Santa Cruz Biotechnology Rabbit polyclonal antibody 1:1000 
GFAP Sigma Rabbit polyclonal antibody 1:5000 
Iba-1 Abcam Goat polyclonal antibody 1:1000 
GAPDH Abcam Mouse monoclonal antibody 1:1000 
GFAP – Glial fibrillary acidic protein; Iba-1 – Ionized calcium binding adaptor molecule 1; GAPDH – Glyceraldehyde-3-phosphate 
dehydrogenase 
Table 2 | Primary antibodies used in immunohistochemistry assay  
Protein Supplier Host Dilution 
GFAP Sigma Mouse monoclonal antibody 1:500 
Iba-1 Abcam Goat polyclonal antibody 1:1000 
IL-1β Abcam Rabbit polyclonal antibody 1:100 
GFAP – Glial fibrillary acidic protein; Iba-1 – Ionized calcium binding adaptor molecule 1; IL-1β – Interleukin-1 beta 
 
8.4    Primers  
Table 3 | Primers used in qPCR 
Gene Primer sequence PCR Fragment size (pb) 
GAPDH 
Forward: GTTTGTGATGGGTGTGAACC 
Reverse:  TCTTCTGAGTGGCAGTGATG 
170 
IL-1β 
Forward: TCCTCTGTGACTCGTGGGAT 
Reverse:  GTTTGGGATCCACACTCTCCA 309 
IL-1RI 
  Forward: GTCGCTGGAGACCGACAAAT 
Reverse:  CAGGTCTGTCCCTCTTGCTG 635 
IL-1RII 
Forward: TCTGGAACTCAAGGTCTTTAAG 
Reverse:  CTTGACCCCAAAGATGCTGGT 336 
TNF-α 
Forward: ATGGGCTCCCTCTCATCAGT 
Reverse:  GCTTGGTGGTTTGCTACGAC 106 
TNFR1 
Forward: TGGCTCATGATCGGGCTTAC 
Reverse:  GTAGGTTCCTTTGTGGCACT 415 
TNFR2 
Forward: CGCATTTGTAGCATCCTGGC 
Reverse: AGGCAGGAGGGCTTCTTTTT 332 
IL-6 
Forward: GCAAGAGACTTCCAGCCAGT 
Reverse:  TTGCCATTGCACAACTCTTTTCT 203 
IL-6R 
Forward: TTGAAGACTATGACAACCAC 
Reverse:  ATACGGTGGGGGAGAAGTCG 227 
 
 
 
iii 
 
 
8.5    Immunofluorescence Assays 
In order to evaluate the expression of the cytokines in glial cells, immunofluorescence assays 
were attempted. Antibodies that recognize each cytokine and the antibodies specific for 
astrocytes (GFAP) and microglia (Iba-1), were used in these assays. But, unfortunately, and in 
spite of many attempts, only the IL-1β antibody (1:100, Abcam) worked in these assays. The 
next panel (Figure 11) shows the co-localization (yellow staining) between IL-1β and GFAP 
at 21 DIV slices, confirming the expression of this cytokine in astrocytes.  
 
 
 
 
 
 
 
 
 
 
Figure 11 | Expression of IL-1β in astrocytes. Detection of GFAP stained astrocytes (green, panel A) with IL-1β (red, panel B) in CA1 region 
of the hippocampus, at 21 DIV slices. The last panel (D) is a magnification of the dotted region in the merge image (C) and clearly shows IL-
1β expression in astrocytes. Confocal images were obtained with a 20x objective. Scale bar, 200µm.  
 
The immunofluorescence assay carried out with IL-1β and Iba-1 antibodies is depicted in 
(Figure 12) and indicated that IL-1β was not expressed in microglia cells. 
 
 
 
 
 
 
 
Figure 12 | Expression of IL-1β in microglia. Detection of Iba-1 stained microglia (green, panel A) with IL-1β (red, panel B) 
in CA3 region of the hippocampus, at 21 DIV slices. IL-1β is not expressed in microglia cells, since no overlap between IL-1β 
and Iba-1 can be found in the merge image (C). Confocal images were obtained with a 20x objective. Scale bar, 200µm.  
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8.6    Theoretical description of the experimental techniques 
8.6.1 Western blot 
The western blot technique (also named as the protein immunoblot) arose from the need to 
create a sensitive assay to detect specific proteins as well as to quantify the protein expression 
from a complex mixture of proteins extracted from cells or tissues. This assay is based on 
protein interaction with a specific antibody and its relative molecular weight. The technique’s 
designation was given by W. Neal Burnette and is derived from the name Southern blot (the 
first transfer process of macromolecules from a gel to an immobilizing matrix). Antibodies can 
be classified as monoclonal antibodies (mAbs), which recognize a single epitope, or as 
polyclonal antibodies, consisting in a combination of immunoglobulin molecules, each 
identifying a different epitope 227. 
The method involves three major steps: 1) separation of a complex protein mixture by size 
through gel electrophoresis, 2) protein transfer onto a membrane and 3) marking the target 
proteins by antibody-antigen specificity 228 .  
Prior to these procedures the protein is extracted from tissues and quantified in order to ensure 
equal loading in all lanes of the gel. Several spectrophotometric methods are available to 
calculate protein concentration. Protein extraction can be achieved through homogenization or 
sonication, always in cold temperature, with an adequate buffer to maintain pH and in presence 
of protease inhibitors to prevent protein damage. The obtained lysates are diluted in a loading 
buffer that contains SDS, glycerol and bromophenol blue. SDS is an anionic detergent that 
binds to hydrophobic regions, causing the protein to acquire a net negative charge. Thus, the 
protein is able to move in an electric field during electrophoresis procedure, toward the positive 
charged electrode 229.  
The most widely used method to separate protein mixtures is the sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE). It maintains polypeptides in a denatured state 
and creates a three-dimensional network, allowing proteins to be discriminated according to 
their molecular weight. The gel density (pore size) affects the separation profile of the proteins, 
since larger molecules are more retarded by the gel than the smaller ones. Samples must be 
previously denatured, in order to ensure that proteins are separated on the basis of size and not 
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charge or three-dimensional structure 229.The SDS-PAGE gel is composed by two types of 
acrylamide gel. Initially, protein samples run through a lower density gel, called stacking gel. 
This gel has lower acrylamide concentration making it highly porous, and concentrates the 
proteins into thin and sharply defined bands, before they enter the resolving gel. The resolving 
gel has higher polyacrylamide content, making gel pores narrower 230. 
Subsequently, the proteins are transferred to a membrane by electroblotting, which relies on the 
same electromobility principles that drive the migration and separation of proteins. Membranes 
are typically made of chemical inert substances, such as nitrocellulose or polyvinylidene 
difluoride (PVDF). In order for the proteins to move from gel to membrane (blot), in a pattern 
that perfectly mirrors their migration positions in the gel, the membrane is placed between the 
gel surface and the positive electrodes in a sandwich. The membrane is immersed in transfer 
buffer, which provides an electrically conducting medium where proteins are soluble 228,229. 
The effectiveness of transfer can be checked by staining the membrane either with Coomassie 
Brilliant Blue or Ponceau S dyes.  
Finally, the transferred proteins can be identified by probing the blot with specific antibodies. 
The first step is the membrane blocking to provide a minimized background of non-specific 
binding between the membrane and the antibody used for detection of the target protein. This 
step is achieved by incubating the membrane in a protein-enriched solution (e.g., bovine serum 
albumin (BSA) or nonfat dried milk) in anionic detergents (e.g., TBST) 228. Following the 
blocking step, the protein of interest is targeted either through a direct or indirect method 
system. In both methods, the antibodies have to be labeled with reporter molecules. The labels 
can be enzymes, fluorescent compounds and metals, that are attached to the primary or 
secondary antibody. The direct method is the simplest, involving one-step. The membrane is 
incubated with a specific primary antibody which is conjugated to the reporter molecule. The 
indirect labeling method involves membrane incubation with an unlabeled primary antibody 
and then with an enzyme conjugated secondary antibody. The secondary-Ab is directed against 
the IgG of the species that provided the primary antibody 231. The most common enzymatic 
detection system used is based on antibodies conjugated to horseradish peroxidase (HRP). This 
enzyme cleaves a chemiluminescent agent, and results in light emission capable of impressing 
an X-ray film. The signal intensity is proportional to the protein quantity on the blot, allowing 
relative precise quantification. All bands are normalized to a housekeeping gene (e.g., 
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Glyceraldehyde 3-phosphate dehydrogenase, α-tubulin, β-actin). Densitometric analysis of 
protein bands is carried out by Image J software 229,230,232. 
 
8.6.2 qPCR 
The polymerase chain reaction (PCR) is a fundamental tool in biological and medical research, 
used to amplify DNA sequences in vitro.  Developed by Kary Mulis in 1983, this biochemical 
technology is described as a thermal cycling process that requires specific designed primers 
(short DNA fragments), containing sequences complementary to the target region, the four 
deoxyribonucleotides thrisphosphate (dNTPs), a thermostable DNA polymerase, and 
magnesium ions which are co-factors of DNA polymerase 233,234. PCR amplification consists in 
three basic steps. Initially, the double-stranded DNA (dsDNA) is heated at a high temperature 
(90-95ºC for 30s to 15 min) to separate it in two single strands (denaturation step). 
Subsequently, the hybridization of the specific oligonucleotide primers for each DNA strand is 
achieved by lowering the temperature, usually between 40ºC and 70ºC (for 30-60s), depending 
on the composition of the primers in terms of each dNTPs. This step, designed as annealing 
step, is then followed by the elongation step in which DNA polymerase synthesizes a new DNA 
strand complementary to the DNA template strand by adding dNTPs at the optimal temperature 
of DNA polymerase (72ºC for 60-120s). The entire cycle is then repeated a pre-determined 
number of times, resulting in an exponential amplification of target molecules during each 
cycle. The PCR specificity depends on the correct hybridization of primer specific sequences 
234. 
The reverse transcriptase PCR (RT-PCR) is a variant of PCR, which turns to be the method of 
choice for RNA detection and quantification. Since it is more sensitive than other techniques 
(e.g Northen Blot, RNase protection assay), it is ideal for detecting mRNA from small amount 
of tissue sample 234. RT-PCR is based on the transcription of RNA molecules into 
complementary DNA (cDNA) by the action of reverse transcriptase enzyme, which can then be 
amplified by PCR 251,234. The discovery of an RNA-dependent DNA polymerase or reverse 
transcriptase was first reported during the study of viral replication by Howard Temin and then 
isolated by Baltimore in 1970 235,236. 
The validity and accuracy of gene expression evaluation is known to be profoundly affected by 
the quality of the starting RNA. It includes both RNA purity (absence of protein and DNA 
contamination and absence of inhibitors) and its integrity. The purity can be assessed by several 
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methods including spectrophotometry. RNA has its absorption maximum at 260 nm. Since 
proteins absorb light at 280 nm the ratio of absorptions at 260 nm and 280 nm (A260/A280) is 
commonly used to assess RNA contamination of protein solutions. There are other sources of 
contamination that produce peaks in the 220-230 nm region such as phenol in the RNA solution. 
Pure RNA has an A260/A280 ratio of 2.1, and a A260/A230 ratio of 2.0 
237. 
Another important version of PCR is the Real-time PCR, which is the most sensitive and 
quantitative method. This technique integrates both detection, amplification and quantification 
of newly synthesized DNA through a fluorescence signal 238. There are two main classes of 
detection systems: fluorescently labelled probes (standard specific detection; e.g., Taqman) and 
dsDNA dyes (non-specific detection; e.g., SYBR Green I) 239. Time, temperature and 
fluorescence are monitored during PCR in real-time instruments 251. 
Real-time PCR analysis can be absolute (number of copies of target DNA molecules) or relative 
(fold-differences in transcription of the target gene, based on an internal reference gene). The 
majority of analyses use relative quantification, since it is easier to carry out and does not 
require a calibration curve as the absolute analysis 239-240. The fluorescence values are recorded 
during each cycle at the end of the elongation step, and the amount the fluorescence signal is 
directly proportional to DNA concentration. A fluorescence threshold is stipulated, known as 
threshold cycle (Ct) or crossing point (CP). Ct is defined as the basal level of detection at which 
the reaction reaches fluorescence intensity above background, in the exponential phase 241. The 
higher the amount of sample DNA of a certain gene, the sooner the accumulated product is 
detected at the threshold level, thus, the lower the Ct value is. 
In the mathematical model developed by Michael W. Pfaffl 242, the relative expression ratio of 
a target gene is calculate based on RT-qPCR efficiency (E) and CP deviation of a treated sample 
versus a control, and expressed in comparison to a reference gene (Figure 13).  The efficiency 
is calculated according to [E=10^(-1/slope)], and the slope value is calculated by plotting the 
CP values vs. log cDNA concentration (ng/µl) from a dilution series. The CP values of each 
target gene are also required and are determined by subtracting the CP values in control and 
sample conditions for both target (ΔCPtarget) and endogenous reference (ΔCPref) genes. The 
normalization of the target gene expression to an endogenous reference gene ensures the 
compensation for inter-PCR variations between runs. Housekeeping genes are usually used, 
since they are expressed in all nucleated cell types and their mRNA synthesis has relatively 
constant levels even in different tissues and under various experimental conditions 243. 
viii 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 | Mathematical model of relative expression ratio in Real-Time PCR (qPCR) (Adapted from Pfaffl 2001)  
 
8.6.3 Gel electrophoresis 
The electrophoretic separation of nucleic acids is usually carried out in agarose gels, instead of 
polyacrylamide gel, since the majority of DNA molecules and their fragments are larger than 
proteins. Therefore, the larger pore size of an agarose gel is required for the separation of 
nucleic acid fragments 231. GelRed is an intercalating nucleic acid fluorophore that, when 
exposed to ultraviolet light, fluoresces with an orange color. It is less toxic and more sensitive 
than ethidium bromide, which, in spite of being a highly mutagenic material, has been the 
predominant dye used for nucleic acid gel staining for decades (GelRed & GelGreen Nucleic 
Acid Gel Stains - Biotium). In agarose gels, as in SDS-PAGE, using an electric field, molecules 
(such as DNA) will run through the pores of the gel. Since DNA has a negative net charge, 
carried by their sugar-phosphate backbone, it will move to the positive electrode and away from 
the negative electrode. Several factors influence how fast the DNA moves, including the 
strength of the electrical field, the concentration of agarose in the gel and the size of the DNA 
molecules. Smaller DNA molecules move through the agarose faster than larger molecules 231.  
8.6.4 Immunohistochemistry 
Based on the specific capacity of antibodies (Abs), immunohistochemistry (IHC) is widely used 
to detect and localize cellular constituents (antigens) in situ, both on individual/cultured cells 
and in a tissue or an organism. It was developed by A. Coons and colleagues in 1941 and it is 
considered to be a helpful tool in the neuroscience field 245.  
The interaction between antigen and Ab can be detected by either direct or indirect methods. 
One of the advantages of the direct method in IHC is the shorter sample staining times. 
Although it is not frequently used, since it produces a weak signal, it generally has high cost 
and low flexibility. In contrast, the indirect method has greater sensitivity. Moreover, secondary 
Abs are relatively inexpensive, available in an array of colors and quality controlled. The 
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disadvantages of this method include higher background signal and potential cross-reactivity 
when performing multiple-labeling experiments. To avoid this problem, Abs that are not raised 
in the same species or Abs of different isotypes must be used 246,247. 
8.6.4.1 Immunofluorescence microscopy 
Immunofluorescence (IF) microscopy uses fluorophores as reporter molecules conjugated to 
Abs. The specimen is submitted to a light of a specific wavelength, which is absorbed by the 
fluorophores (excitation) and then part of this energy is re-emitted at longer specific 
wavelengths (emission). Fluorescent staining can be visualized with standard fluorescent 
microscopy and also with confocal microscopes 246–248. 
The confocal microscope focuses a spot of light onto a single point at a specific depth in the 
tissue.  For that, it requires a very bright source of illumination, which is supplied by a laser 
whose light is reflected by multiple mirrors, with the objective to scan the laser across the 
sample. The fluorescence emitted from the illuminated material passes across a pinhole and is 
collected and brought to an image at a suitable light detector. Confocal microscopy not only 
provides information on structures in an individual plane but is also capable of collecting 
multiple serial optical sections from thick specimens, in the z direction generating a z-stack. 
Thus, through computer programs it enables the reconstruction of an optical image of the cell 
in a three-dimensional structure. Another advantage of this optical imaging technique is the 
blockage of sample fluorescence at the pinhole, eliminating the out-of-focus signals. Therefore, 
this increases the resolution at the cost of less signal since not all emitted light is collected. 
However, brighter images can be acquired in comparison to standard epifluorescence 249.  
The outcome of an immunohistochemical reaction depends on the properties of the Abs used 
and the tissue preparation, mainly its fixation 250. To preserve cells and tissues in reproducible 
and life‐like manner, generally, immunostaining is carried out on fixed and permeabilized 
tissues (solubilize membranes) prepared by aldehydes (e.g., paraformaldehyde or 
formaldehyde). Further permeabilization can be accomplished with a detergent, such as Triton 
X-100, in order to guarantee that Abs are able to access the intracellular antigens. Subsequently, 
the tissue is incubated with a blocking solution, thus avoiding non-specific protein binding sites 
(e.g., BSA, powder milk). The following steps involve the incubation of primary and secondary 
Ab (coupled with a fluorophore). The multiple immunolabeling depends on whenever the 
primary Abs are produced in the same species (sequential dual labelling is performed) or in 
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different species (tissue can be incubated simultaneously with both Abs). In this way, the false 
positive staining is avoided. The false negatives must also be assessed to evade problems of the 
specificity of an antibody 231,248,248. The last step consists in mounting the samples, in order to 
protect the tissue and avoid the quenching of fluorescence.  
 
8.7    qPCR primer specificity  
 8.7.1 Standard and melting curve analysis 
The following figures illustrate the qPCR standard and melting curves for each analyzed gene. 
For the analysis of the transcript expression, 5-fold serial dilutions of the cDNA net solutions 
were used to create a standard curve for each gene. As explained in section 9.6.2 the Pfaffl 
relative quantification method requires the crossing point (CP) determination indicated by the 
threshold (red line) in the normalized fluorescence vs. cycle plot (panels A of Figures 14-21). 
The standard curves (panels B of Figures 14-21) were created by plotting the CP vs. the log 
concentration of cDNA (ng/µL). The parameters calculated using the standard curve are also 
indicated in panels B. Those parameters were the efficiency (E), relative expression rate (R) 
and slope value (M). Slope value is required in order to calculate the amplification efficiency 
[E=10^(-1/slope)] for the Pfaffl equation and should be between the interval of values 
3.1<M<3.7. The value E, resulted from the standard curve of each gene, is a measure of the 
overall efficiency of the reaction and should be included in the [0.85; 1.10] interval. R2 gives a 
measure of the fitting of the linear regression and the linearity of the PCR assay and the value 
should be superior to 0.98 inclusive. The assessment of the reaction specificity was also 
evaluated by melting curve analysis (panels C of Figures 14-21). The visualization of one 
single peak indicates a specific amplification of the targeted gene. All plots were created using 
Corbett software (Corbett Life Science).  
IL-1RII mRNA expression level was also analyzed. However, when the PCR amplification of 
IL-1RII mRNA was performed, to obtain the standard curve, the first two dilutions achieved a 
Ct value of 40 and the last three dilutions were not amplified. After several attempts, we 
concluded that this receptor has a very low mRNA expression in our system.   
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Figure 14 | qPCR Standard and melting curves analysis for the GAPDH gene – endogenous control. A) PCR amplification 
plot for the GAPDH gene. B) Parameters calculated using standard curve created by plotting CP vs. the log concentration of 
cDNA (ng/µL). C) Assessment of reaction specificity by melting curve analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 | qPCR Standard and melting curves analysis for the interleukin-1β (IL-1β) gene. A) PCR amplification plot 
for the IL-1β gene. B) Parameters calculated using standard curve created by plotting CP vs. the log concentration of cDNA 
(ng/µL). C) Assessment of reaction specificity by melting curve analysis.  
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Figure 16 | qPCR Standard and melting curves analysis for the interleukin 1 receptor type I (IL1R1) gene. A) PCR 
amplification plot for the IL1R1 gene. B) Parameters calculated using standard curve created by plotting CP vs. the log 
concentration of cDNA (ng/µL). C) Assessment of reaction specificity by melting curve analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 | qPCR Standard and melting curves analysis for the tumor necrosis factor alpha (TNF-α) gene. A) PCR 
amplification plot for the TNF-α gene. B) Parameters calculated using standard curve created by plotting CP vs. the log 
concentration of cDNA (ng/µL). C) Assessment of reaction specificity by melting curve analysis.  
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Figure 18 | qPCR Standard and melting curves analysis for the tumor necrosis factor receptor-1 (TNFR1) gene. A) PCR 
amplification plot for the TNFR1 gene. B) Parameters calculated using standard curve created by plotting CP vs. the log 
concentration of cDNA (ng/µL). C) Assessment of reaction specificity by melting curve analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 | qPCR Standard and melting curves analysis for the tumor necrosis factor receptor-2 (TNFR2) gene. A) PCR 
amplification plot for the TNFR2 gene. B) Parameters calculated using standard curve created by plotting CP vs. the log 
concentration of cDNA (ng/µL). C) Assessment of reaction specificity by melting curve analysis.  
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Figure 20 | qPCR Standard and melting curves analysis for the interleukin-6 (IL-6) gene. A) PCR amplification plot for 
the IL-6 gene. B) Parameters calculated using standard curve created by plotting CP vs. the log concentration of cDNA (ng/µL). 
C) Assessment of reaction specificity by melting curve analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 | qPCR Standard and melting curves analysis for the interleukin-6 receptor (IL-6R) gene. A) PCR amplification 
plot for the IL-6R gene. B) Parameters calculated using standard curve created by plotting CP vs. the log concentration of 
cDNA (ng/µL). C) Assessment of reaction specificity by melting curve analysis.  
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8.8    Agarose gels analysis 
Alternatively to the melting curve attained at the end of the run of real-time qPCR, the primers 
specificity can be analyzed by gel electrophoresis. All real-time qPCR primers must generate a 
single amplicon of the correct size on agarose gels. As shown in panels C of Figures 14-20 the 
melting curves of each gene contain a single peak with no shoulders, and the agarose gels 
(Figure 21) also revealed a single band corresponding to the predicted amplicon length of each 
gene.  
 
   
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 | Gel analysis of the qPCR products. 2% agarose gel shows the PCR product amplified with each pair of specific 
primers. MWM, molecular weight marker; lane 1 TNFα (106 pb), lane 2, TNFR1 (415 pb), lane 3, TNFR2 (332 pb), lane 4 IL-
1β (309 pb), lane 5 IL-1RI (635 pb), lane 6 IL-1RII (336 pb), lane 7 IL-6 (203 pb), lane 8 IL-6R (227 pb), lane 9 GAPDH (170 
pb).  
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